JPY3,556.00
1.08% today
Tokyo, Sep 03, 08:10 am CET
ISIN
JP3475350009
Symbol
4568
Index

DAIICHI SANKYO Stock price

JPY3,553.00
-67.00 1.85% 1M
-112.00 3.06% 6M
-799.00 18.36% YTD
-2,463.00 40.94% 1Y
-584.00 14.12% 3Y
+400.67 12.71% 5Y
+2,811.00 378.84% 10Y
+2,684.67 309.17% 20Y
Tokyo, Closing price Wed, Sep 03 2025
+35.00 0.99%
ISIN
JP3475350009
Symbol
4568
Index
Industry

Key metrics

Basic
Market capitalization
JPY6.6t
Enterprise Value
JPY6.2t
Net debt
positive
Cash
JPY624.9b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
22.1 | 20.6
P/S
3.5 | 3.2
EV/Sales
3.2 | 3.0
EV/FCF
negative
P/B
4.2
Dividends
DPS
JPY78.00
Yield 1Y | 5Y
2.2% | 1.3%
Growth 1Y | 5Y
30.0% | 23.6%
Payout 1Y | 3Y
38.5% | 44.1%
Increased
4 Years
Financials (TTM | estimate)
Revenue
JPY1.9t | JPY2.1t
EBITDA
JPY405.5b | JPY417.6b
EBIT
JPY335.7b | JPY28.2t
Net Income
JPY295.9b | JPY315.6b
Free Cash Flow
JPY-64.7b
Growth (TTM | estimate)
Revenue
14.1% | 11.1%
EBITDA
25.7% | 4.2%
EBIT
28.8% | 8,402.0%
Net Income
29.1% | 6.7%
Free Cash Flow
-116.0%
Margin (TTM | estimate)
Gross
78.5%
EBITDA
21.1% | 19.9%
EBIT
17.4%
Net
15.4% | 15.1%
Free Cash Flow
-3.4%
Financial Health
Equity Ratio
47.0%
Return on Equity
18.2%
ROCE
12.6%
ROIC
13.3%
Debt/Equity
0.1
More
EPS
JPY159.3
FCF per Share
JPY-34.9
Short interest
-
Employees
19k
Rev per Employee
JPY100.7m
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a DAIICHI SANKYO forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a DAIICHI SANKYO forecast:

Buy
95%
Hold
5%

Financial data from DAIICHI SANKYO

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,924,678 1,924,678
14% 14%
100%
- Direct Costs 413,094 413,094
1% 1%
21%
1,511,584 1,511,584
19% 19%
79%
- Selling and Administrative Expenses 736,433 736,433
9% 9%
38%
- Research and Development Expense 441,201 441,201
13% 13%
23%
405,493 405,493
26% 26%
21%
- Depreciation and Amortization 69,835 69,835
12% 12%
4%
EBIT (Operating Income) EBIT 335,658 335,658
29% 29%
17%
Net Profit 295,873 295,873
29% 29%
15%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Hiroyuki Okuzawa
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today